Synthesis of Novel 1,2,3-Triazole-Linked Isatin and 5-Fluoroisatin Hybrids: Anticancer and Antibacterial Evaluation Supported by Molecular Docking, Molecular Dynamics, and ADMET Studies

Imagine the human body as a bustling city where cells are the citizens. Sometimes, a few citizens go rogue, multiplying wildly and ignoring traffic lights; this is cancer. Other times, tiny invaders like bacteria sneak in, building fortresses that our current defenses can't break; this is infection. For decades, scientists have been trying to build better "keys" to unlock these problems. One popular strategy is called "molecular hybridization." Think of it like a Lego set: instead of building a single, simple block, scientists take two different, powerful blocks—one known to fight cancer and another known to fight bacteria—and snap them together into one super-block. The hope is that this new hybrid will be smarter and stronger than either piece alone. To make sure these new blocks fit perfectly into the locks of our body's cells, scientists use "click chemistry," a method so precise and easy it's like snapping two Lego bricks together with a satisfying click, rather than trying to glue them with messy, unpredictable chemicals.

In this study, a team of researchers decided to build a new set of these super-blocks using two famous ingredients: isatin (a chemical structure known for its ability to mess with cancer cells) and 1,2,3-triazole (a ring-shaped molecule that acts like a sturdy, stable connector). They wanted to see if they could create a hybrid molecule that could act as a dual-threat weapon against both lung and breast cancer, as well as stubborn bacterial infections. They didn't just build them; they tested them in the lab, watched how they behaved under a microscope, and even used powerful computer simulations to see how they would dance with the proteins inside our cells.

The Great Chemical Construction Project

The researchers started by designing two series of these hybrid molecules. They took a base structure called isatin (and a slightly tweaked version called 5-fluoroisatin, which is like the isatin wearing a special "fluorine" hat) and attached a flexible, three-carbon chain to it. This chain acted like a long, flexible arm. At the end of this arm, they used their "click chemistry" magic to snap on a ring of atoms called a 1,2,3-triazole, which was then connected to various different aromatic rings (think of these as different colored flags or decorations).

They created a whole library of these hybrids, labeled 3a–g and 4a–g. The only difference between the two main groups was that the 4-series had that special fluorine hat on the isatin base, while the 3-series did not. They tested how well these new creations were made, and the results were excellent: the "click" reaction worked smoothly, producing high yields of pure, clean compounds without needing messy cleanup steps.

The Battle Against Cancer

Next, the team put these new molecules to the test against two types of cancer cells: A549 (lung cancer) and MCF-7 (breast cancer). They used a standard test called the MTT assay, which essentially asks the cells, "Are you still alive?" by measuring how much purple dye they can turn.

The results were exciting. Most of the new hybrids showed they could kill cancer cells, but some were champions. The standout hero was compound 4g. This molecule, which had a nitro group (a specific chemical decoration) on its flag, was incredibly effective.

• Against lung cancer (A549), it had an IC₅₀ (the amount needed to kill half the cells) of 11.35 ± 1.16 µg/mL.
• Against breast cancer (MCF-7), its IC₅₀ was 14.56 ± 0.34 µg/mL.

To put this in perspective, they compared it to methotrexate, a well-known cancer drug used as a benchmark. Methotrexate had an IC₅₀ of 10.20 ± 1.82 µg/mL for lung cancer and 15.63 ± 0.57 µg/mL for breast cancer. This means 4g was almost as strong as the famous drug, and in the case of breast cancer, it was actually slightly more potent!

When they looked at the cells under a microscope after treating them with these compounds, they saw the classic signs of apoptosis (programmed cell death). The cancer cells shrank, their membranes bubbled (blebbing), and they lost their ability to stick together. It was as if the cells had received a "self-destruct" signal that they couldn't ignore.

The Battle Against Bacteria

The researchers also tested these hybrids against bacteria. They pitted them against Gram-positive bacteria (like Staphylococcus aureus and Bacillus cereus) and Gram-negative bacteria (like E. coli and Pseudomonas aeruginosa).

Here, the results were a bit more selective. The hybrids were like specialized soldiers: they were very good at fighting the Gram-positive bacteria but struggled against the Gram-negative ones.

• The champion against bacteria was compound 4a (the one with the plain, unsubstituted phenyl ring). It created an inhibition zone (a clear circle where bacteria couldn't grow) of 18.0 ± 1.30 mm against Staphylococcus aureus. This was even slightly better than the standard antibiotic control, which made a 17.0 ± 1.34 mm zone.
• However, against the Gram-negative bacteria, most of the compounds were weak or inactive. The researchers noted that the tough outer shell of Gram-negative bacteria likely blocked the hybrids from getting inside, much like a fortress wall stopping an attacker.

The Computer Simulation Detective Work

Since they couldn't watch the molecules interact with the cancer's "control center" (a protein called EGFR) in real-time, the team used computer simulations.

1. Molecular Docking: They virtually dropped the molecules into the EGFR protein's active site to see how well they fit. Compound 4d (with a fluorine decoration) fit the best, with a docking score of -8.041 kcal/mol, which is very close to the reference drug's score of -8.978 kcal/mol. This suggested it would bind tightly.
2. Molecular Dynamics: They then ran a 200-nanosecond simulation (a movie of the molecules moving) to see if the bond held up. The results showed that the complexes were stable. The molecules didn't wiggle out of place; they stayed snug in the pocket, forming hydrogen bonds with key parts of the protein, just like a key staying locked in a door.

The "Drug-Likeness" Check

Finally, before these molecules could ever become real medicines, they need to pass a safety check called ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). The computer predicted that these hybrids generally looked like good drug candidates: they were small enough to be swallowed, had the right balance of fat-loving and water-loving properties, and wouldn't be immediately rejected by the body. However, the simulations also flagged a potential warning: some of the compounds might have issues with liver toxicity (DILI) or heart rhythm (hERG inhibition), suggesting that while they are promising leads, they need more work to be safe for humans.

The Big Picture

What did the researchers learn?

• The Fluorine Factor: Adding that fluorine atom to the isatin base (creating the 4-series) generally made the molecules better at fighting both cancer and bacteria compared to the non-fluorinated versions.
• The Power of the Nitro Group: For killing cancer, having an electron-withdrawing group like a nitro group (in 4g) was a huge advantage.
• The Power of the Plain Ring: For killing bacteria, a simple, unsubstituted ring (in 4a) worked best.

The paper concludes that these 1,2,3-triazole-linked isatin hybrids are a very promising starting point. They suggest that by tweaking the decorations on the molecule, scientists could create a "Swiss Army knife" drug that fights both cancer and infection. While the computer models and lab tests are very encouraging, the authors are careful to note that these are just the first steps. The molecules have shown they can work, but they haven't been tested in living animals or humans yet. The journey from a cool chemical discovery in a lab to a real medicine is long, but this study has definitely built a strong foundation for the next leg of the trip.